Figure 4. Recurrence of AF among Patients with AF Conversion: Sotalol versus Amiodarone The studies and data elements are organized as in Figure 2. The studies were homogeneous (I2 = 2%), thus the fixed effect model was employed for meta-analysis. The combined (weighted mean) relative risk of AF recurrence is 1,462 (95% CI: 1.260 to 1.697, p<0.001) indicating a significantly higher common relative risk of AF recurrence for sotalol. The figure also indicates that with longer follow up time the risk of AF recurrence increases more in patients who received sotalol comped to those who received amiodarone. The relative risk of AF recurrence on sotalol became significant at 6 months follow up (p=0.027) and became more significant during 1 year follow up (p<0.001).